Current Allergy and Asthma Reports

, Volume 11, Issue 1, pp 7–11

Interleukin-33 in Asthma: How Big of a Role Does It Play?

Article

Abstract

In complex disorders such as asthma and allergic disease, the goal for developing disease-modifying biotherapeutics is to find a target that is a central instigator of immunologic activity. Interleukin (IL)-33 seems to be such a molecule, as it is one of the earliest-released signaling molecules following epithelial damage and can orchestrate the recruitment and activation of the cells responsible for disease. Unregulated IL-33 activity leads to activation of T-helper type 2 cells, mast cells, dendritic cells, eosinophils, and basophils, ultimately leading to increased expression of cytokines and chemokines that define the disease. As such, IL-33 is an attractive candidate for therapeutic intervention with the goal of ameliorating disease. This review focuses on the role of IL-33 in promoting and maintaining the asthma phenotype.

Keywords

Asthma Interleukin-33 ST2 Interleukin-1 family 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Barksby HE, Lea SR, Preshaw PM, Taylor JJ: The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 2007, 149:217–225.CrossRefPubMedGoogle Scholar
  2. 2.
    Sims JE, Nicklin MJ, Bazan JF, et al.: A new nonmenclature for IL-1-family genes. Trends Immunol 2001, 22:536–537.CrossRefPubMedGoogle Scholar
  3. 3.
    Robinson D, Shibuya K, Mui A, et al.: IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 1997, 7:571–581.CrossRefPubMedGoogle Scholar
  4. 4.
    Arend WP: Interleukin-1 receptor antagonist. Adv Immunol 1993, 54:167–227.CrossRefPubMedGoogle Scholar
  5. 5.
    Schmitz J, Owyang A, Oldham E, et al.: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479–490.CrossRefPubMedGoogle Scholar
  6. 6.
    •• Luthi AU, Cullen SP, McNeela EA, et al.: Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009, 31:84–98, It was believed that IL-33 was activated by caspases, similar to other members of the IL-1 family; however, this article demonstrated that IL-33 was active in the uncleaved form and was only released following necrosis caused by cell damage.CrossRefPubMedGoogle Scholar
  7. 7.
    Carriere V, Roussel L, Ortega N, et al.: IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 2007, 104:282–287.CrossRefPubMedGoogle Scholar
  8. 8.
    Maier JA, Statuto M, Ragnotti G: Endogenous interleukin 1 alpha must be transported to the nucleus to exert its activity in human endothelial cells. Mol Cell Biol 1994, 14:1845–1851.PubMedGoogle Scholar
  9. 9.
    Buryskova M, Pospisek M, Grothey A, et al.: Intracellular interleukin-1alpha functionally interacts with histone acetyltransferase complexes. J Biol Chem 2004, 279:4017–4026.CrossRefPubMedGoogle Scholar
  10. 10.
    Dunne A, O’Neill LA: The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003, 2003:re3.Google Scholar
  11. 11.
    Klemenz R, Hoffman S, Werenskiold AK: Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci U S A 1989, 86:5708–5712.CrossRefPubMedGoogle Scholar
  12. 12.
    Tominaga A: A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 1989, 258:301–304.CrossRefPubMedGoogle Scholar
  13. 13.
    Pecaric-Petkovic T, Didichenko SA, Kaempfer S, et al.: Human basophils and eosinophils are the direct target leukocytes of the novel IL-1-family member IL-33. Blood 2009, 113:1396–1397.Google Scholar
  14. 14.
    Smithgall MD, Comeau MR, Yoon BR, et al.: IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008, 20:1019–1030.CrossRefPubMedGoogle Scholar
  15. 15.
    Neill DR, Wong SH, Bellosi A, et al.: Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010, 464:1367–1370.CrossRefPubMedGoogle Scholar
  16. 16.
    Rossler U, Thomassen E, Hultner L, et al.: Secreted and membrane-bound isoforms of T1, an orphan receptor related to IL-1-binding proteins, are differently expressed in vivo. Dev Biol 1995, 168:86–97.CrossRefPubMedGoogle Scholar
  17. 17.
    Chackerian AA, Oldham ER, Murphy EE, et al.: IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007, 179:2551–2555.PubMedGoogle Scholar
  18. 18.
    Lohning M, Stroehmann A, Coyle AJ, et al.: T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 1998, 95:6930–6935.CrossRefPubMedGoogle Scholar
  19. 19.
    Xu D, Chan WL, Leung BP, et al.: Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998, 187:787–794.CrossRefPubMedGoogle Scholar
  20. 20.
    Coyle AJ, Lloyd CM, Tian J, et al.: Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 1999, 190:895–902.CrossRefPubMedGoogle Scholar
  21. 21.
    Townsend MJ, Fallon PG, Matthews DJ, et al.: T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 2000, 191:1069–1075.CrossRefPubMedGoogle Scholar
  22. 22.
    Kurowska-Stolarska M, Kewin P, Murphy G, et al.: IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008, 181:4780–4790.PubMedGoogle Scholar
  23. 23.
    Komai-Koma M, Xu D, Li Y, et al.: IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007, 37:2779–2786.CrossRefPubMedGoogle Scholar
  24. 24.
    • Rank MA, Kobayahi T, Kozaki H, et al.: IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol 2009, 123:1047–1054, This article demonstrated that DCs respond to IL-33 through the ST2 receptor. When these stimulated DCs were cultured with naïve T cells, they were able to induce expression of IL-5 and IL-13.CrossRefPubMedGoogle Scholar
  25. 25.
    Mayuzumi N, Matsushima H, Takashima A: IL-33 promotes DC development in BM culture by triggering GM-CSF production. Eur J Immunol 2009, 39:3331–3342.CrossRefPubMedGoogle Scholar
  26. 26.
    Iikura M, Suto H, Kajiwara N, et al.: IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007, 87:971–978.CrossRefPubMedGoogle Scholar
  27. 27.
    Moulin D, Donze O, Talabot-Ayer D, et al.: Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007, 40:216–225.CrossRefPubMedGoogle Scholar
  28. 28.
    Allakhverdi Z, Smith DE, Comeau MR, Delespesse G: Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007, 179:2051–2054.PubMedGoogle Scholar
  29. 29.
    Drube S, Heink S, Walter S, et al.: The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood 2010, 115:3899–3906.CrossRefPubMedGoogle Scholar
  30. 30.
    Allakhverdi Z, Comeau MR, Smith DE, et al.: CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. J Allergy Clin Immunol 2009, 123:472–478.CrossRefPubMedGoogle Scholar
  31. 31.
    Pushparaj PN, Tay HK, H’ng SC, et al.: The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A 2009, 106:9773–9778.CrossRefPubMedGoogle Scholar
  32. 32.
    Hayakawa H, Hayakawa M, Kume A, Tominaga S: Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007, 282:26369–26380.CrossRefPubMedGoogle Scholar
  33. 33.
    • Kearley J, Buckland KF, Mathie SA, Lloyd CM: Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 2009, 179:772–781, Using a murine model of allergic disease, these authors demonstrated that blockade of ST2 prevented development of airway hyperreactivity and an increase of Th2 cells into the lung. IL-33 levels were increased during active lung inflammation.CrossRefPubMedGoogle Scholar
  34. 34.
    Cherry WB, Yoon J, Bartemes KR, et al.: A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008, 121:1484–1490.CrossRefPubMedGoogle Scholar
  35. 35.
    Chow JY, Wong CK, Cheung PF, Lam CW: Intracellular signaling mechanisms regulating the activation of human eosinophils by the novel Th2 cytokine IL-33: implications for allergic inflammation. Cell Mol Immunol 2010, 7:26–34.CrossRefPubMedGoogle Scholar
  36. 36.
    Suzukawa M, Iikiura M, Koketsu R, et al.: An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol 2008, 181:5981–5989.PubMedGoogle Scholar
  37. 37.
    Prefontaine D, Nadigel J, Chouiali F, et al.: Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010, 125:752–754.CrossRefPubMedGoogle Scholar
  38. 38.
    Reh DD, Wang Y, Ramanathan M Jr, Lane AP: Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am J Rhinol Allergy 2010, 24:105–109.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Asthma and Allergic Disease Center, Box 801355University of Virginia Health SystemsCharlottesvilleUSA

Personalised recommendations